8 February 2021 - partnership agreement

The company has announced another partnership agreement to speed up the CE marking of its Covid rapid antigen test and also support Covid-19 testing in low and middle income countries.  The partnership is with Mologic, a leading developer of advanced lateral flow and rapid diagnostic technologies and should provide Avacta with a faster route to market and additional manufacturing capacity.  The shares have been pretty volatile over the last few months, dropping to 105p in December, but remain a BUY ON WEAKNESS.  

  . . .

This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.

Already a member, log in HERE.